An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Approximately 45 hyperphosphatemic CKD patients not on dialysis will be entered into this
study at approximately 20 sites within Europe and 5-10 in Australia. The purpose of this
study is to determine if sevelamer carbonate tablets dosed three times a day (TID) is an
effective treatment for the control of serum phosphorous levels in hyperphosphatemic CKD
patients not on dialysis. Total length of participation is approximately 14 weeks.